All In Biotech

Free tool

FAERS Monitor: Enhertu

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761139 or its brand name (Enhertu, Fam-Trastuzumab Deruxtecan-Nxki). Reports on generic versions are filed under their own applications.

Reports

10,910

Serious

8,277

76% of reports

Hospitalization

2,628

Death reported

2,791

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death1,336
  • nausea1,288
  • disease progression1,257
  • interstitial lung disease1,100
  • fatigue858
  • off label use846
  • diarrhoea632
  • vomiting593
  • pneumonitis441
  • decreased appetite410
  • asthenia407
  • no adverse event381
  • alopecia366
  • dyspnoea348
  • metastases to central nervous system279

Reports by year received

View as table
YearReports
20161
20194
2020380
2021717
20221,274
20231,808
20242,028
20252,248
20262,450

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,249 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
interstitial lung diseaseSignal1,10044.842.346,089
metastases to central nervous systemSignal27942.637.911,055
pneumonitisSignal44131.728.912,894
disease progressionSignal1,25720.719.623,415
no adverse eventSignal3814.13.7882
alopeciaSignal3663.63.3689
decreased appetiteSignal4103.43.1701
nauseaSignal1,2883.13.01,948
deathSignal1,3363.02.81,843
vomitingSignal5932.42.3510
fatigueSignal8582.12.0529
astheniaSignal4072.11.9234
diarrhoea6321.91.8271
off label use8461.91.7352
dyspnoea3481.21.110

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.